ProMIS Neurosciences (PMN) Competitors $0.92 +0.02 (+1.88%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PMN vs. TARA, LPTX, MGX, XFOR, INMB, JMAC, ADVM, CRDL, DERM, and ANROShould you be buying ProMIS Neurosciences stock or one of its competitors? The main competitors of ProMIS Neurosciences include Protara Therapeutics (TARA), Leap Therapeutics (LPTX), Metagenomi (MGX), X4 Pharmaceuticals (XFOR), INmune Bio (INMB), Maxpro Capital Acquisition (JMAC), Adverum Biotechnologies (ADVM), Cardiol Therapeutics (CRDL), Journey Medical (DERM), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical products" industry. ProMIS Neurosciences vs. Protara Therapeutics Leap Therapeutics Metagenomi X4 Pharmaceuticals INmune Bio Maxpro Capital Acquisition Adverum Biotechnologies Cardiol Therapeutics Journey Medical Alto Neuroscience Protara Therapeutics (NASDAQ:TARA) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking. Is TARA or PMN more profitable? Protara Therapeutics' return on equity of -55.96% beat ProMIS Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -55.96% -49.06% ProMIS Neurosciences N/A -636.20%-130.32% Does the MarketBeat Community prefer TARA or PMN? Protara Therapeutics received 34 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 66.67% of users gave Protara Therapeutics an outperform vote. CompanyUnderperformOutperformProtara TherapeuticsOutperform Votes3666.67% Underperform Votes1833.33% ProMIS NeurosciencesOutperform Votes2100.00% Underperform VotesNo Votes Which has preferable valuation and earnings, TARA or PMN? ProMIS Neurosciences has higher revenue and earnings than Protara Therapeutics. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$40.42M-$2.82-1.91ProMIS Neurosciences$10K3,007.39-$13.21M-$0.10-9.20 Do analysts prefer TARA or PMN? Protara Therapeutics currently has a consensus price target of $22.67, indicating a potential upside of 320.53%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Protara Therapeutics is more favorable than ProMIS Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00ProMIS Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to TARA or PMN? In the previous week, ProMIS Neurosciences' average media sentiment score of 0.00 beat Protara Therapeutics' score of -0.12 indicating that ProMIS Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment Protara Therapeutics Neutral ProMIS Neurosciences Neutral Which has more risk & volatility, TARA or PMN? Protara Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Do institutionals & insiders believe in TARA or PMN? 38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are held by institutional investors. 12.5% of Protara Therapeutics shares are held by insiders. Comparatively, 4.4% of ProMIS Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryProtara Therapeutics beats ProMIS Neurosciences on 9 of the 15 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricProMIS NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.07M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-9.2010.5991.3417.19Price / Sales3,007.39195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book4.605.104.794.78Net Income-$13.21M$151.51M$120.07M$225.60M7 Day Performance-1.08%-2.15%-1.89%-1.24%1 Month Performance-3.66%-3.14%11.45%3.36%1 Year Performance-20.00%11.50%30.61%16.58% ProMIS Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNProMIS Neurosciences1.0717 of 5 stars$0.92+1.9%N/A-20.2%$30.07M$10,000.00-9.206Positive NewsTARAProtara Therapeutics2.3557 of 5 stars$5.61-6.2%$22.67+304.0%+196.2%$115.73MN/A-2.1230LPTXLeap Therapeutics1.2897 of 5 stars$3.01+2.0%$7.50+149.2%-1.0%$115.34M$1.50M-1.5340Positive NewsGap DownMGXMetagenomi2.1309 of 5 stars$3.05-5.9%$16.67+446.4%N/A$114.14M$55.08M0.00236High Trading VolumeXFORX4 Pharmaceuticals4.3341 of 5 stars$0.67-0.3%$3.50+423.9%-16.4%$113.94MN/A-8.2280Gap DownINMBINmune Bio1.4805 of 5 stars$5.07+6.7%$20.00+294.5%-55.7%$112.41M$42,000.00-2.1810JMACMaxpro Capital AcquisitionN/A$8.34+7.8%N/A+837.6%$112.00MN/A0.002,021Gap DownADVMAdverum Biotechnologies4.2094 of 5 stars$5.32-0.9%$27.83+423.2%-40.0%$110.67M$1M-0.90190Analyst DowngradeNews CoverageCRDLCardiol Therapeutics2.2579 of 5 stars$1.34+0.4%$8.75+555.4%+44.0%$109.07M$60,000.00-3.4120Analyst ForecastAnalyst RevisionNews CoverageGap DownDERMJourney Medical2.548 of 5 stars$5.01-1.6%$9.38+87.1%N/A$104.66M$79.18M-5.3690ANROAlto Neuroscience3.2563 of 5 stars$3.83flat$20.00+422.2%N/A$103.30M$210,000.000.00N/AGap Up Related Companies and Tools Related Companies Protara Therapeutics Alternatives Leap Therapeutics Alternatives Metagenomi Alternatives X4 Pharmaceuticals Alternatives INmune Bio Alternatives Maxpro Capital Acquisition Alternatives Adverum Biotechnologies Alternatives Cardiol Therapeutics Alternatives Journey Medical Alternatives Alto Neuroscience Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PMN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMN Stock Alerts